Market Overview:
The global acetylspiramycin market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in the market can be attributed to factors such as rising prevalence of infectious diseases, increasing demand for acetylspiramycin tablets and capsules, and growing investments by key players in R&D activities. However, the high cost of treatment is expected to restrain the growth of this market during the forecast period. Based on type, the global acetylspiramycin market can be segmented into 99% purity type, 98% purity type, and others. The 99% purity type segment is expected to account for a major share of the global acetylspiramycin market during the forecast period owing to its high efficacy and better patient compliance rates as compared with other types available in the market.
 Industry Outlook.svg)
Product Definition:
Acetylspiramycin is a macrolide antibiotic produced by Streptomyces venezuelae. It inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit.
99% Purity Type:
99% purity type is a high-performance liquid chromatography (HPLC) grade of Acetyl Spiramycin. It has been developed to meet the highest quality control and performance standards set by the pharmaceutical industry. 99% Purity Type offers several advantages over other grades such as cost, time & labor savings, greater reliability on HPLC results and most important peak purity as per requirement which gives it an edge over its competitors in this market.
98% Purity Type:
98% purity type is a high-purity form of any substance, which contains less than 2% impurities by weight. It is used in pharmaceutical and biotechnology industries for manufacturing various products such as antibiotics, hormones, enzymes and proteins. 98% purity type has higher content of active ingredients compared to other forms such as 75%, 90%, 95%, 99% etc., which makes it more effective for the final product.
Application Insights:
Acetylspiramycin tablets were the most prominent application segment and accounted for a revenue share of over 70.0% in 2017. The drug is used to treat respiratory diseases such as tuberculosis, bronchiectasis, and pneumonia. It is also employed in the treatment of skin infections due to its anti-inflammatory property. In addition, it has been found useful in treating urinary tract infections owing to its antibacterial property against E coli bacteria that cause these infections. These factors are anticipated to drive product demand over the forecast period.
The acetylspiramycin capsule segment is expected witness significant growth during the forecast period owing to increasing usage as an antibiotic for acute respiratory diseases such as bronchitis and asthma attacks across various regions including North America.
Regional Analysis:
North America was the largest regional market for acetylspiramycin in 2017. The region is expected to maintain its dominance over the forecast period owing to high product demand and favorable reimbursement policies in U.S., which has resulted in a higher penetration of spiramycin tablets and capsule formulation.
Asia Pacific is anticipated to be one of the fastest growing regions with CAGR exceeding 6% during the forecast period due to increasing incidence rate of MDR TB, rising healthcare expenditure levels, improving economic conditions especially in India & China as well as government initiatives favoring generic drugs manufacturing industry are some major factors driving growth across this region. In addition Spiramin (acetylspirAMYCIN) Tablets manufactured by Sun Pharmaceutical Industries Ltd.
Growth Factors:
- Increasing demand from the pharmaceutical and biotechnology industries for acetylspiramycin as an antibiotic agent.
- Growing research and development activities for the use of acetylspiramycin in new drug formulations.
- Rising prevalence of infectious diseases that can be treated with acetylspiramycin.
- Technological advancements in the production of acetylspiramycin that will lead to lower manufacturing costs and increased availability of the drug worldwide.
Scope Of The Report
Report Attributes
Report Details
Report Title
Acetylspiramycin (CAS 24916-51-6) Market Research Report
By Type
99% Purity Type, 98% Purity Type, Others
By Application
Acetylspiramycin Tablets, Acetylspiramycin Capsule
By Companies
Guangzhou Baiyunshan Pharm, HPGC, CSPC, Lukang Pharm, Tongda Pharm, Zhongxin Pharm, Shantou Jinshi Pharm, Top Fond, Bailu Pharm, Zhejiang Medicine, Chemifarma, Filozzo, Sogeval, Rottendorf Pharm, Merial
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
236
Number of Tables & Figures
166
Customization Available
Yes, the report can be customized as per your need.
Global Acetylspiramycin (CAS 24916-51-6) Market Report Segments:
The global Acetylspiramycin (CAS 24916-51-6) market is segmented on the basis of:
Types
99% Purity Type, 98% Purity Type, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Acetylspiramycin Tablets, Acetylspiramycin Capsule
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Guangzhou Baiyunshan Pharm
- HPGC
- CSPC
- Lukang Pharm
- Tongda Pharm
- Zhongxin Pharm
- Shantou Jinshi Pharm
- Top Fond
- Bailu Pharm
- Zhejiang Medicine
- Chemifarma
- Filozzo
- Sogeval
- Rottendorf Pharm
- Merial
 Market Overview.svg)
Highlights of The Acetylspiramycin (CAS 24916-51-6) Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- 99% Purity Type
- 98% Purity Type
- Others
- By Application:
- Acetylspiramycin Tablets
- Acetylspiramycin Capsule
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Acetylspiramycin (CAS 24916-51-6) Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
 Market Statistics.svg)
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Acetylspiramycin is a synthetic antibiotic. It is used to treat infections caused by certain types of bacteria. Acetylspiramycin works by stopping the growth of these bacteria.
Some of the key players operating in the acetylspiramycin (cas 24916-51-6) market are Guangzhou Baiyunshan Pharm, HPGC, CSPC, Lukang Pharm, Tongda Pharm, Zhongxin Pharm, Shantou Jinshi Pharm, Top Fond, Bailu Pharm, Zhejiang Medicine, Chemifarma, Filozzo, Sogeval, Rottendorf Pharm, Merial.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Acetylspiramycin (CAS 24916-51-6) Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Acetylspiramycin (CAS 24916-51-6) Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Acetylspiramycin (CAS 24916-51-6) Market - Supply Chain
4.5. Global Acetylspiramycin (CAS 24916-51-6) Market Forecast
4.5.1. Acetylspiramycin (CAS 24916-51-6) Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Acetylspiramycin (CAS 24916-51-6) Market Size (000 Units) and Y-o-Y Growth
4.5.3. Acetylspiramycin (CAS 24916-51-6) Market Absolute $ Opportunity
5. Global Acetylspiramycin (CAS 24916-51-6) Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Acetylspiramycin (CAS 24916-51-6) Market Size and Volume Forecast by Type
5.3.1. 99% Purity Type
5.3.2. 98% Purity Type
5.3.3. Others
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Acetylspiramycin (CAS 24916-51-6) Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Acetylspiramycin (CAS 24916-51-6) Market Size and Volume Forecast by Application
6.3.1. Acetylspiramycin Tablets
6.3.2. Acetylspiramycin Capsule
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Acetylspiramycin (CAS 24916-51-6) Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Acetylspiramycin (CAS 24916-51-6) Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Acetylspiramycin (CAS 24916-51-6) Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Acetylspiramycin (CAS 24916-51-6) Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Acetylspiramycin (CAS 24916-51-6) Demand Share Forecast, 2019-2026
9. North America Acetylspiramycin (CAS 24916-51-6) Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Acetylspiramycin (CAS 24916-51-6) Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Acetylspiramycin (CAS 24916-51-6) Market Size and Volume Forecast by Application
9.4.1. Acetylspiramycin Tablets
9.4.2. Acetylspiramycin Capsule
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Acetylspiramycin (CAS 24916-51-6) Market Size and Volume Forecast by Type
9.7.1. 99% Purity Type
9.7.2. 98% Purity Type
9.7.3. Others
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Acetylspiramycin (CAS 24916-51-6) Demand Share Forecast, 2019-2026
10. Latin America Acetylspiramycin (CAS 24916-51-6) Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Acetylspiramycin (CAS 24916-51-6) Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Acetylspiramycin (CAS 24916-51-6) Market Size and Volume Forecast by Application
10.4.1. Acetylspiramycin Tablets
10.4.2. Acetylspiramycin Capsule
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Acetylspiramycin (CAS 24916-51-6) Market Size and Volume Forecast by Type
10.7.1. 99% Purity Type
10.7.2. 98% Purity Type
10.7.3. Others
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Acetylspiramycin (CAS 24916-51-6) Demand Share Forecast, 2019-2026
11. Europe Acetylspiramycin (CAS 24916-51-6) Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Acetylspiramycin (CAS 24916-51-6) Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Acetylspiramycin (CAS 24916-51-6) Market Size and Volume Forecast by Application
11.4.1. Acetylspiramycin Tablets
11.4.2. Acetylspiramycin Capsule
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Acetylspiramycin (CAS 24916-51-6) Market Size and Volume Forecast by Type
11.7.1. 99% Purity Type
11.7.2. 98% Purity Type
11.7.3. Others
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Acetylspiramycin (CAS 24916-51-6) Demand Share, 2019-2026
12. Asia Pacific Acetylspiramycin (CAS 24916-51-6) Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Acetylspiramycin (CAS 24916-51-6) Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Acetylspiramycin (CAS 24916-51-6) Market Size and Volume Forecast by Application
12.4.1. Acetylspiramycin Tablets
12.4.2. Acetylspiramycin Capsule
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Acetylspiramycin (CAS 24916-51-6) Market Size and Volume Forecast by Type
12.7.1. 99% Purity Type
12.7.2. 98% Purity Type
12.7.3. Others
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Acetylspiramycin (CAS 24916-51-6) Demand Share, 2019-2026
13. Middle East & Africa Acetylspiramycin (CAS 24916-51-6) Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Acetylspiramycin (CAS 24916-51-6) Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Acetylspiramycin (CAS 24916-51-6) Market Size and Volume Forecast by Application
13.4.1. Acetylspiramycin Tablets
13.4.2. Acetylspiramycin Capsule
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Acetylspiramycin (CAS 24916-51-6) Market Size and Volume Forecast by Type
13.7.1. 99% Purity Type
13.7.2. 98% Purity Type
13.7.3. Others
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Acetylspiramycin (CAS 24916-51-6) Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Acetylspiramycin (CAS 24916-51-6) Market: Market Share Analysis
14.2. Acetylspiramycin (CAS 24916-51-6) Distributors and Customers
14.3. Acetylspiramycin (CAS 24916-51-6) Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Guangzhou Baiyunshan Pharm
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. HPGC
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. CSPC
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Lukang Pharm
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Tongda Pharm
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Zhongxin Pharm
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Shantou Jinshi Pharm
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Top Fond
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Bailu Pharm
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Zhejiang Medicine
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Chemifarma
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Filozzo
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. Sogeval
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. Rottendorf Pharm
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. Merial
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
